Choosing first-line treatment for metastatic urothelial carcinoma
Official title: Criteria for Selecting First-line Metastatic Treatment for Patients With Urothelial Carcinoma: Observational, Multicenter, Real-world Study
Run by University Hospital, Strasbourg, France · NCT07339878 · Data updated 2026-11-12
This study will look at adults with metastatic urothelial carcinoma treated since October 2024 to see which patient features and clinician reasons lead to choosing platinum-based chemotherapy instead of enfortumab vedotin plus pembrolizumab as first-line therapy.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 50 (estimated) |
| Sponsor | University Hospital, Strasbourg, France Academic / other |
| Drugs / interventions | Enfortumab, Pembrolizumab, avelumab, chemotherapy |
| Locations | 1 site (Strasbourg) |
| Status | Recruiting |
| Started | April 20, 2025 |
| Main results expected | April 2026 |
| Study ends | April 20, 2026 |
| Registry record updated | January 14, 2026 |
| Trial ID | NCT07339878 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (≥18 years) with metastatic urothelial carcinoma who started first-line systemic therapy at or after October 2024 and receive care at CHU de Strasbourg.
✕Probably not a fit
Patients who began treatment before October 2024, who have non-urothelial cancers, or who refuse consent are not eligible and are unlikely to benefit from the study's findings.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational cohort will collect clinical and treatment data on adults with metastatic urothelial carcinoma who began first-line systemic therapy from October 2024 onward at CHU de Strasbourg. Investigators will record patient characteristics, tumor features, comorbidities, laboratory results, and documented clinician reasons for choosing platinum-based chemotherapy versus enfortumab vedotin plus pembrolizumab. No investigational interventions are given; data are obtained from medical records and clinician or patient reports with consent. Analyses will describe factors associated with selection of platinum-based therapy and the frequency of reasons cited by treating physicians.
Why it matters
Potential benefit: If successful, the study could help doctors and patients choose the most appropriate first-line therapy by clarifying which patient features lead to selection of platinum-based chemotherapy over enfortumab vedotin plus pembrolizumab.
How similar studies have gone: Randomized trials like EV-302 established the efficacy of enfortumab vedotin plus pembrolizumab, but real-world studies specifically examining why clinicians choose platinum-based chemotherapy instead are limited.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients over 18 years of age * Metastatic urothelial carcinoma * Treated with first-line metastatic therapy since October 2024 Exclusion Criteria: * Patient who expressed opposition to participating in the study
Where it's running
-
Service Oncologie Médicale - CHU de Strasbourg - France
Strasbourg, France Recruiting
Study contacts
- Study coordinator: Philippe Barthélémy, MD
- Email: philippe.barthelemy@chru-strasbourg.fr
- Phone: 33 3 88 12 76 70
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Ivonescimab plus enfortumab vedotin vs pembrolizumab plus enfortumab vedotin in untreated locally advanced or metastatic urothelial cancer
This trial tests if adding ivonescimab to enfortumab vedotin works better than pembrolizumab plus enfortumab vedotin for people with untreated locally advanced or metastatic urothelial cancer.
-
Imaging Test for Metastatic Urothelial and Breast C cancers and NSCLC
This imaging study tests how well the imaging agent works in people with metastatic urothelial cancer, various breast cancers, or NSCLC.
-
Dual-target Nectin-4 and HER2 CAR-NK therapy for advanced urothelial carcinoma
This treatment will try dual-target CAR-NK cells that recognize Nectin‑4 and HER2 in adults with relapsed or metastatic urothelial carcinoma after standard therapies.
-
GB-4362 combined with enfortumab vedotin and pembrolizumab for advanced urothelial cancer
This study will test adding GB-4362 to enfortumab vedotin and pembrolizumab to see if it lowers treatment-related side effects like nerve damage in adults with advanced or metastatic urothelial cancer.
-
Nerve effects of enfortumab vedotin in people with urothelial cancer
We will see how nerve testing and patient-reported symptoms change in adults with urothelial cancer who are starting enfortumab vedotin.
-
Pembrolizumab maintenance after initial enfortumab vedotin plus pembrolizumab for frontline metastatic urothelial cancer
This trial will test whether continuing pembrolizumab after an 18-week course of enfortumab vedotin plus pembrolizumab helps people with previously untreated metastatic urothelial carcinoma.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.